Pacific Biosciences Of California Free Cash Flow (FCF) History (PACB)
Pacific Biosciences Of California reported −$113.9M in free cash flow for fiscal 2025, an increase of $98.3M from the previous fiscal year, with a free cash flow margin of −71.20%.
View full Pacific Biosciences Of California company overviewPacific Biosciences Of California free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$113.9M | $98.3M | — | −71.20% |
| 2024 | 2024-12-31 | −$212.2M | $55.8M | — | −137.81% |
| 2023 | 2023-12-31 | −$268.0M | $11.9M | — | −133.66% |
| 2022 | 2022-12-31 | −$280.0M | −$162.8M | — | −218.20% |
| 2021 | 2021-12-31 | −$117.1M | −$135.6M | — | −89.73% |
| 2020 | 2020-12-31 | $18.5M | $99.6M | — | +23.40% |
| 2019 | 2019-12-31 | −$81.1M | −$12.9M | — | −89.28% |
| 2018 | 2018-12-31 | −$68.3M | $9.7M | — | −86.85% |
| 2017 | 2017-12-31 | −$78.0M | −$1.8M | — | −83.40% |
| 2016 | 2016-12-31 | −$76.1M | −$25.2M | — | −83.93% |
| 2015 | 2015-12-31 | −$50.9M | $2.2M | — | −54.86% |
| 2014 | 2014-12-31 | −$53.1M | −$22.3M | — | −87.59% |
| 2013 | 2013-12-31 | −$30.7M | $47.8M | — | −109.09% |
| 2012 | 2012-12-31 | −$78.5M | $33.7M | — | −302.22% |
| 2011 | 2011-12-31 | −$112.3M | $15.0M | — | −331.51% |
| 2010 | 2010-12-31 | −$127.3M | −$47.2M | — | −7601.85% |
| 2009 | 2009-12-31 | −$80.0M | — | — | −59270.37% |
Pacific Biosciences Of California quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$37.1M | −$7.2M | — | −95.21% |
| Q1 2026 | 2026-03-31 | −$47.7M | −$2.3M | — | −128.39% |
| Q4 2025 | 2025-12-31 | −$19.9M | $12.3M | — | −44.64% |
| Q3 2025 | 2025-09-30 | −$18.8M | $27.5M | — | −48.89% |
| Q2 2025 | 2025-06-30 | −$29.9M | $25.8M | — | −75.26% |
| Q1 2025 | 2025-03-31 | −$45.4M | $34.1M | — | −122.32% |
| Q4 2024 | 2024-12-31 | −$32.3M | $27.3M | — | −82.26% |
| Q3 2024 | 2024-09-30 | −$46.3M | $19.8M | — | −115.72% |
| Q2 2024 | 2024-06-30 | −$55.7M | −$11.7M | — | −154.78% |
| Q1 2024 | 2024-03-31 | −$79.6M | $18.9M | — | −205.00% |
| Q4 2023 | 2023-12-31 | −$59.6M | $5.9M | — | −102.10% |
| Q3 2023 | 2023-09-30 | −$66.0M | $1.2M | — | −118.53% |
| Q2 2023 | 2023-06-30 | −$44.0M | $20.6M | — | −92.51% |
| Q1 2023 | 2023-03-31 | −$98.4M | −$15.7M | — | −252.99% |
| Q4 2022 | 2022-12-31 | −$65.5M | −$30.9M | — | −239.35% |
| Q3 2022 | 2022-09-30 | −$67.2M | −$25.5M | — | −208.11% |
| Q2 2022 | 2022-06-30 | −$64.6M | −$47.3M | — | −182.09% |
| Q1 2022 | 2022-03-31 | −$82.7M | −$59.2M | — | −249.20% |
| Q4 2021 | 2021-12-31 | −$34.5M | −$20.2M | — | −95.92% |
| Q3 2021 | 2021-09-30 | −$41.8M | −$23.4M | — | −119.74% |
| Q2 2021 | 2021-06-30 | −$17.3M | $6.8M | — | −56.46% |
| Q1 2021 | 2021-03-31 | −$23.5M | −$98.8M | — | −81.06% |
| Q4 2020 | 2020-12-31 | −$14.3M | $4.0M | — | −57.02% |
| Q3 2020 | 2020-09-30 | −$18.3M | −$255,000 | — | −96.13% |
| Q2 2020 | 2020-06-30 | −$24.1M | −$5.9M | — | −126.34% |
| Q1 2020 | 2020-03-31 | $75.2M | $101.8M | — | +482.41% |
| Q4 2019 | 2019-12-31 | −$18.3M | $722,000 | — | −65.60% |
| Q3 2019 | 2019-09-30 | −$18.1M | −$3.8M | — | −82.54% |
| Q2 2019 | 2019-06-30 | −$18.2M | −$2.3M | — | −73.81% |
| Q1 2019 | 2019-03-31 | −$26.6M | −$7.4M | — | −161.74% |
| Q4 2018 | 2018-12-31 | −$19.0M | $2.2M | — | −97.53% |
| Q3 2018 | 2018-09-30 | −$14.3M | $6.8M | — | −78.58% |
| Q2 2018 | 2018-06-30 | −$15.9M | $404,000 | — | −73.47% |
| Q1 2018 | 2018-03-31 | −$19.1M | $222,000 | — | −98.73% |
| Q4 2017 | 2017-12-31 | −$21.3M | −$5.7M | — | −85.26% |
| Q3 2017 | 2017-09-30 | −$21.1M | −$2.9M | — | −89.59% |
| Q2 2017 | 2017-06-30 | −$16.3M | $5.4M | — | −80.99% |
| Q1 2017 | 2017-03-31 | −$19.3M | $1.4M | — | −77.62% |
| Q4 2016 | 2016-12-31 | −$15.6M | −$14.0M | — | −60.46% |
| Q3 2016 | 2016-09-30 | −$18.2M | −$1.9M | — | −72.37% |
| Q2 2016 | 2016-06-30 | −$21.7M | −$13.2M | — | −104.51% |
| Q1 2016 | 2016-03-31 | −$20.7M | $3.9M | — | −108.35% |
| Q4 2015 | 2015-12-31 | −$1.6M | $14.2M | — | −4.39% |
| Q3 2015 | 2015-09-30 | −$16.2M | −$9.8M | — | −116.61% |
| Q2 2015 | 2015-06-30 | −$8.4M | $5.6M | — | −33.88% |
| Q1 2015 | 2015-03-31 | −$24.6M | −$7.9M | — | −139.57% |
| Q4 2014 | 2014-12-31 | −$15.8M | −$1.2M | — | −93.67% |
| Q3 2014 | 2014-09-30 | −$6.4M | −$24.9M | — | −31.15% |
| Q2 2014 | 2014-06-30 | −$14.1M | $2.6M | — | −123.28% |
| Q1 2014 | 2014-03-31 | −$16.7M | $1.1M | — | −143.73% |
| Q4 2013 | 2013-12-31 | −$14.7M | $4.0M | — | −160.67% |
| Q3 2013 | 2013-09-30 | $18.5M | $36.6M | — | +249.20% |
| Q2 2013 | 2013-06-30 | −$16.7M | $7.4M | — | −275.91% |
| Q1 2013 | 2013-03-31 | −$17.9M | −$260,000 | — | −320.40% |
| Q4 2012 | 2012-12-31 | −$18.7M | −$2.5M | — | −317.51% |
| Q3 2012 | 2012-09-30 | −$18.1M | $8.0M | — | −653.13% |
| Q2 2012 | 2012-06-30 | −$24.1M | $10.9M | — | −330.81% |
| Q1 2012 | 2012-03-31 | −$17.6M | $17.3M | — | −175.45% |
| Q4 2011 | 2011-12-31 | −$16.2M | $18.2M | — | −130.26% |
| Q3 2011 | 2011-09-30 | −$26.1M | — | — | −248.21% |
| Q2 2011 | 2011-06-30 | −$35.0M | — | — | −329.12% |
| Q1 2011 | 2011-03-31 | −$35.0M | — | — | −12945.93% |
| Q3 2010 | 2010-09-30 | −$34.4M | — | — | −15632.73% |
Pacific Biosciences Of California free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $18.5M to −$113.9M, a net decrease of $132.4M. Pacific Biosciences Of California's latest reported quarter, Q2 2026, generated −$37.1M in free cash flow, a decrease of $7.2M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Pacific Biosciences Of California filings at SEC.gov ↗